China Resources Pharmaceutical Group Limited

SEHK:3320 Voorraadrapport

Marktkapitalisatie: HK$34.8b

China Resources Pharmaceutical Group Inkomsten in het verleden

Verleden criteriumcontroles 5/6

China Resources Pharmaceutical Group has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 8% per year. China Resources Pharmaceutical Group's return on equity is 8.5%, and it has net margins of 1.5%.

Belangrijke informatie

4.3%

Groei van de winst

4.4%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie5.6%
Inkomstengroei8.0%
Rendement op eigen vermogen8.5%
Nettomarge1.5%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17
Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Opbrengsten en kosten

Hoe China Resources Pharmaceutical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SEHK:3320 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24250,4833,77725,5880
31 Mar 24247,5933,81625,4200
31 Dec 23244,7043,85425,2520
30 Sep 23232,5643,57323,9060
30 Jun 23224,6563,38222,9610
31 Mar 23224,5873,51822,7830
31 Dec 22218,1833,50021,9990
30 Sep 22221,4873,72422,2470
30 Jun 22211,7883,71921,1930
31 Mar 22196,2263,28819,6740
31 Dec 21193,0213,07219,3930
30 Sep 21191,4952,86919,6670
30 Jun 21187,5542,62619,7010
31 Mar 21179,5122,72019,0920
31 Dec 20168,7622,77618,1970
30 Sep 20171,8732,68319,1370
30 Jun 20174,9562,57820,1220
31 Mar 20181,0542,79321,2330
31 Dec 19182,6902,93721,8130
30 Sep 19183,4173,67021,9840
30 Jun 19173,9384,18720,9300
31 Mar 19165,6793,73720,0690
31 Dec 18166,6263,49420,3220
30 Sep 18163,7343,46619,5400
30 Jun 18154,8523,30918,0620
31 Mar 18142,2962,95915,7950
31 Dec 17143,6882,90115,0870
30 Sep 17143,2522,75914,2770
30 Jun 17142,2762,60213,3800
31 Mar 17142,0032,57713,3950
31 Dec 16140,3162,52613,2790
30 Sep 16132,2532,16112,5340
30 Jun 16129,3131,88912,2740
31 Mar 16123,7702,10311,7660
31 Dec 15122,7852,38811,6920
31 Dec 14108,5752,1169,9550
31 Dec 1391,3132,0619,2480

Kwaliteitswinsten: 3320 has high quality earnings.

Groeiende winstmarge: 3320's current net profit margins (1.5%) are higher than last year (1.5%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 3320's earnings have grown by 4.3% per year over the past 5 years.

Versnelling van de groei: 3320's earnings growth over the past year (11.7%) exceeds its 5-year average (4.3% per year).

Winst versus industrie: 3320 earnings growth over the past year (11.7%) exceeded the Pharmaceuticals industry 6.4%.


Rendement op eigen vermogen

Hoge ROE: 3320's Return on Equity (8.5%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden